Targeted therapy with BRAF-MEK inhibitors is an effective treatment for patients with advanced melanoma that cannot be surgically removed or has spread to other areas of the body.
Archive | Of Interest
Scientists identify key driver in BRAF inhibitor resistant melanoma
Posted in Melanoma News, Health Professionals, Of Interest
Moffitt researchers identify metastasis driver in BRAF inhibitor resistant melanoma
TAMPA, Fla. — Targeted therapy with BRAF-MEK inhibitors is an effective treatment for patients with advanced melanoma that cannot be surgically removed or has spread to other areas of the body.
Posted in Melanoma News, Health Professionals, Of Interest
Targeted combination immunotherapy improved survival in stage III melanoma
Response: Based on molecular biology analysis, a substantial proportion of melanomas are driven by mutations of BRAF resulting in an ongoing growth activating signal. Based on the key role of BRAF several multiple kinase molecules have been developed in order to target this crucial pathway. These medications have shown to improve progression free survival and […]
Posted in Melanoma News, Health Professionals, Of Interest
Adjuvant therapy in stage IIIA melanoma: Cost vs Benefit of gene profiling
Response: Indications for adjuvant therapy for resected, high-risk melanoma is a controversial and rapidly-evolving topic in melanoma treatment.
Posted in Melanoma News, Health Professionals, Of Interest
